Document is current
Any future updates will be listed below
-
Authors
-
Funding
Funding for this research was provided by:
Julius-Maximilians-Universität Würzburg
- License Information
-
More Information
Article History
Received: 24 November 2024
Accepted: 19 February 2025
First Online: 6 March 2025
Declarations
:
: L. Seefried has received honoraria for lectures and advice from Amgen, AM-Pharma, Alexion, Biomarin, Chiesi, GedeonRichter, GSK/Haleon, Inozyme, Ipsen, KyowaKirin, Medi, Novartis, Stadapharm, Theramex, and Ultragenyx and research grants to the Institution (University of Würzburg) from Alexion, Chiesi, Kyowa Kirin. F. Genest has received honoraria for lectures from Abbvie, Alexion, and Lilly. E.T. Rush has received consulting fees from Alexion AstraZeneca Rare Disease, Ultragenyx Pharmaceuticals, Kyowa Kirin, Inozyme Pharma, Ipsen SA, Be Bio, Inc, honoraria for lectures from Alexion AstraZeneca Rare Disease, Kyowa Kirin, and Inozyme Pharma, research support from Alexion AstraZeneca Rare Disease, and Ultragenyx Pharmaceuticals.
: This overview manuscript does not report original human or animal data.
